Suppr超能文献

Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.

作者信息

Mahadevia Parthiv J, Malinoski Frank J

出版信息

Arch Pediatr Adolesc Med. 2007 May;161(5):519-20; author reply 520. doi: 10.1001/archpedi.161.5.519.

Abstract
摘要

相似文献

1
Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Arch Pediatr Adolesc Med. 2007 May;161(5):519-20; author reply 520. doi: 10.1001/archpedi.161.5.519.
2
Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Arch Pediatr Adolesc Med. 2006 Oct;160(10):1070-6. doi: 10.1001/archpedi.160.10.1070.
3
Economic analysis of palivizumab in infants with congenital heart disease.
Pediatrics. 2004 Dec;114(6):1606-11. doi: 10.1542/peds.2004-0224.
4
Health economics and RSV.
Paediatr Respir Rev. 2009 Jun;10 Suppl 1:12-3. doi: 10.1016/S1526-0542(09)70006-5.
6
[Respiratory syncytial virus infections and preventive options].
Ned Tijdschr Geneeskd. 2000 Apr 8;144(15):724-5.
8
Questions about palivizumab (Synagis).
Pediatrics. 1999 Feb;103(2):535; author reply 535-6.
10
The cost and safety of multidose use of palivizumab vials.
Clin Pediatr (Phila). 2008 Mar;47(2):160-3. doi: 10.1177/0009922807306994. Epub 2007 Sep 27.

引用本文的文献

1
Structure-guided design of small-molecule therapeutics against RSV disease.
Expert Opin Drug Discov. 2016;11(6):543-556. doi: 10.1517/17460441.2016.1174212. Epub 2016 Apr 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验